Claims

1. Use of a RAS(ON) inhibitor in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the cancer comprises:

(a) a first RAS mutation that is G12C and a second RAS mutation at a position selected from the group consisting of H95, R68, G13 and Q61, or a second RAS mutation that is selected from the group consisting of Y96C, Y96F, Y96H, Y96N, Y96S; or

(b) a first RAS mutation at position G12 selected from the group consisting of G12H, G12I, G12K, G12M, G12N, G12P, G12Q, G12T, G12W and G12Y,

wherein the cancer is resistant to treatment with a RAS(OFF) inhibitor.